dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Pai, Sara I. |
dc.contributor.author | Cohen, Ezra E. W. |
dc.contributor.author | Lin, Derrick |
dc.contributor.author | Fountzilas, George |
dc.contributor.author | Kim, Edward S. |
dc.contributor.author | Mehlhorn, Holger |
dc.contributor.author | Basté Rotllan, Neus |
dc.date.accessioned | 2021-04-19T13:34:55Z |
dc.date.available | 2021-04-19T13:34:55Z |
dc.date.issued | 2019-12-26 |
dc.identifier.citation | Pai SI, Cohen EEW, Lin D, Fountzilas G, Kim ES, Mehlhorn H, et al. SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Transl Med. 2019 Dec 26;17(1):429. |
dc.identifier.issn | 1479-5876 |
dc.identifier.uri | https://hdl.handle.net/11351/5875 |
dc.description | Biomarcador; Carcinoma de cèl·lules escamoses de cap i coll; PD-L1 |
dc.description.sponsorship | This study was sponsored by AstraZeneca. The protocol for this study was developed by the sponsor (AstraZeneca) and advisors. Data were collected collaboratively by the sponsor and clinical investigators. Statisticians employed by the sponsor analyzed the data. All authors participated in the preparation, review, and approval of the manuscript; and decision to submit the manuscript for publication. |
dc.language.iso | eng |
dc.publisher | BMC |
dc.relation.ispartofseries | Journal of Translational Medicine;17(1) |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Prognosi |
dc.subject | Cap - Càncer |
dc.subject | Coll - Càncer |
dc.subject.mesh | Squamous Cell Carcinoma of Head and Neck |
dc.subject.mesh | Prognosis |
dc.title | SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1186/s12967-019-02182-1 |
dc.subject.decs | carcinoma de células escamosas de cabeza y cuello |
dc.subject.decs | pronóstico |
dc.relation.publishversion | https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-019-02182-1 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Pai SI] Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, GRJ 9 904G, Boston, MA 02114, USA. [Cohen EEW] UC San Diego Health System, Moores Cancer Center, La Jolla, CA, USA. [Lin D] Massachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit Street, GRJ 9 904G, Boston, MA 02114, USA. Massachusetts Eye and Ear, Boston, MA, USA. [Fountzilas G] Aristotle University of Thessaloniki, Thessaloniki, Greece. [Kim ES] Levine Cancer Institute, Atrium Health, Charlotte, NC, USA. [Mehlhorn H] Universitaet sklinikum Leipzig, Klinik und Poliklinik fur HNO-Heilkunde, Leipzig, Germany. [Baste N] Servei d’Oncologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 31878938 |
dc.identifier.wos | 000513524800002 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |